DUBLIN–(BUSINESS WIRE)–The Board of Directors of Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near vision restoration, announced today that it has appointed Dr. Gerd Auffarth, M.D., Ph.D. to the board. The board also announc…
Category: Business
Ocata Therapeutics to Host Conference Call and Webcast to Provide Corporate Update for the Second Quarter of 2015
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced today that it will host a conference call on Thursday, August 6, 2015 at 4:30 p.m. EDT, during which it will provide a corporate update for the second quarter of 2015. Interested parties may access the call live by dialing (888) 312-3054 (US) or (719) 325-2449 (international) and using conference ID 2737702. A live audio webcast of the presentation will b
NovaBay Pharmaceuticals to Hold Second Quarter 2015 Conference Call on August 13
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today announced that it will report second quarter financial results after market close on Thursday, August 13. Management will hold an investment community conference call to discuss financial results and provide a company update. DATE: Thursday, August 13, 2015 TIME:
ACADIA Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2015
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous sy…
Inotek Pharmaceuticals Announces Conversion of $21 Million Principal Amount of 5.0% Convertible Senior Notes due 2020
LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that $20,970,000 of its 5.0% Convertible Senior Notes due 2020 (the “2020 Notes”) maturing February 15, 2020 have been converted into shares of common stock of the Company. The 2020 Notes converted into approximately 3.86 million shares, includ
Glaukos Corporation to Release Second Quarter 2015 Financial Results After Market Close on August 12
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release second quarter 2015 financial results after the market close on Wednesday, August 12, 2015. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on Au
Opternative Revolutionizes Eye Exams with Launch of Online, Ophthalmologist-Issued Prescription Service for Glasses and Contacts
CHICAGO–(BUSINESS WIRE)–Opternative, the world’s first online eye exam service, is now available to provide consumers with a convenient and affordable physician-issued prescription for glasses or contacts. By using a computer and smartphone, consumers can take a 25-minute or less eye exam from the comfort of home and receive a prescription within 24 hours to use at any online or neighborhood optical retailer. Opternative exams cost $40 for a prescription for glasses or contacts and $60 for bo
Research and Markets: Global Wet (Neovascular / Exudative) Macular Degeneration Pipeline Insights Report 2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/rnv8jx/wet_neovascular) has announced the addition of the “Wet (Neovascular / Exudative) Macular Degeneration-Pipeline Insights” report to their offering. Wet (Ne…
Visionworks and Davis Vision Launch ‘Let’s Go See’ – Children’s Eye Health Campaign to Raise Awareness of Importance of Annual Eye Exams
SAN ANTONIO–(BUSINESS WIRE)–Just in time for back-to-school, Visionworks and Davis Vision is launching ‘Let’s Go See,’ a cause marketing initiative focused on raising awareness about the importance of children receiving an annual eye exam. Reports from The Center for Health in Schools show that about 60% of students classified as problem learners have some sort of undetected visual problem. “Many parents take their children in for routine doctor and dental check-ups, but often wait for their
Bascom Palmer Eye Institute Ranked Nation’s #1 in Ophthalmology for the 12th Consecutive Year
MIAMI–(BUSINESS WIRE)–For the 12th consecutive year — and the 14th time overall — Bascom Palmer Eye Institute at UHealth – the University of Miami Health System has been ranked the nation’s best in ophthalmology by U.S. News & World Report in its 2015-2016 Best Hospitals edition. Every year since the rankings began 25 years ago, Bascom Palmer has been ranked either first or second in the country. “At Bascom Palmer, the well-being of our patients inspires us to excel in eye care, vision re
pSivida CEO to Speak at Controlled Release Society Annual Meeting Workshop in Edinburgh, Scotland, This Weekend
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida CEO to speak at Controlled Release Society Annual Meeting Workshop in Edinburgh, Scotland, this weekend.
Inotek Pharmaceuticals Appoints Richard N. Spivey PharmD, Ph.D. to Board of Directors
LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek Appoints ophthalmology development leader Spivey to Board of Directors
Ophthotech Announces New Senior Leadership Appointments
NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation announced the appointment of David T. Shima, Ph.D. as Chief Scientific Officer and Henric Bjarke as Senior Vice President and Chief Commercial Officer.
NovaBay Pharmaceuticals Plan of Compliance Accepted by NYSE
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing novel approaches for the global eye care market including revolutionary natural non-antibiotic antimicrobial products, today announced that the New York Stock Exchange has accepted NovaBay’s plan to regain compliance with the NYSE MKT’s continued listing standards. As previously disclosed, the NYSE notified the Company on April 28, 2015 that it had fall
Tobii AB: U.S. Congress Approves Bill to Make It Easier for People with Communication Disabilities to Receive Funding for Assistive Technology
STOCKHOLM–(BUSINESS WIRE)–Regulatory News: U.S. Congress has passed a new bill called The Steve Gleason Act that improves the possibility for people with communication disabilities to receive public funding of speech-generating devices (SGDs) through Medicare. President Obama’s subsequent signing of the bill is expected to take place shortly. For Tobii Dynavox, which develops and sells both eye tracking and touchscreen-based assistive technology solutions, the new bill is likely to introduce
Aerpio Therapeutics Announces Positive Results of a Phase 2a Study of AKB-9778 in Diabetic Macular Edema: The TIME-2 Trial
CINCINNATI–(BUSINESS WIRE)–Aerpio Therapeutics, a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced top-line results from its TIME-2 study of AKB-9778 in DME. The combination of AKB-9778 (dosed at 15 mg BID) and Lucentis® (ranibizumab injection) provided a clinically significant benefit in reduction of central subfield thickness (CST) compared to Lucentis® alone (p=0.008). In association with this improvement in CST, a positive trend also sh
Ocata Therapeutics Receives New U.S. Patent for Its RPE Therapy for Macular Degenerative Diseases
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that it continues to fortify the patent protection covering its retinal pigment epithelium (RPE) transplant technology for macular degeneration with the issuance by the United States Patent and Trademark Office (USPTO) of U.S. Patent No 9,080,150. “The issuance of this 9th U.S. patent in our global RPE portfolio represents yet another example of the
Second Sight Announces Expansion of Argus II Availability in Europe
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, today announced the first commercial implants of the Argus® II Retinal Prosthesis System (“Argus II”) have been performed in Austria and Turkey, and the first implant in Spain through a distribution agreement with IMEX has been performed. IMEX is the largest
pSivida Announces Positive Top Line Results From Investigator-Sponsored Phase II Study of Medidur™ for Uveitis
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida announces top line results from investigator-sponsored Phase II study of Medidur for uveitis. Statistically significant reduction in recurrence of disease and visual acuity.
Human Color Vision Gives People the Ability to See Nanoscale Differences
WASHINGTON–(BUSINESS WIRE)–Researchers have harnessed the human eye’s ability to detect subtle color differences and identify ‘thin films’ that differ in thickness by a few nanometers, about the width of a single virus.